VV116 as a potential treatment for COVID-19

References

• McCarthy MW. Novel Strategies for the Treatment of COVID-19. Drugs R D. 2022;22(4):257–262.
   Google Scholar
• Lee TC, Morris AM, Grover SA, et al. Outpatient therapies for COVID-19: how do we choose? Open Forum Infect Dis. 2022;9(3):ofac008.
   PubMedGoogle Scholar
• Callaway E. Coronavirus variant XBB.1.5 rises in the United States - is it a global threat? Nature. 2023;613(7943):222–223.
   PubMedGoogle Scholar
• Graham F. Daily briefing: is subvariant XBB.1.5 a global threat? Nature. 2023;22:2241–2249 .
   Google Scholar
• Leung K, Lau EHY, Wong CKH, et al. Estimating the transmission dynamics of SARS-CoV-2 Omicron BF.7 in Beijing after the adjustment of zero-COVID policy in November - December 2022. Nat Med. 2023;17:1.
   Google Scholar
• COVID-19 update: resistance to bebtelovimab. Med Lett Drugs Ther. 2022; 64(1664):e192.
   Google Scholar
• COVID-19 updates: FDA restricts use of sotrovimab. Med Lett Drugs Ther. 2022;64(1648):64.
   PubMedGoogle Scholar
• Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with covid-19. N Engl J Med. 2022;386(15):1397–1408.
   PubMed Web of Science ®Google Scholar
• Lee TC, Pogue JM, McCreary EK, et al. What is the place in therapy for nirmatrelvir/ritonavir? BMJ Evid Based Med. 2022;37:1811–1819.
   Google Scholar
• Greasley SE, Noell S, Plotnikova O, et al. Structural basis for the in vitro efficacy of nirmatrelvir against SARS-CoV-2 variants. J Biol Chem. 2022;298(6):101972.
   PubMedGoogle Scholar
• Guy-Alfandary S, Zhurat S, Berlin M, et al. Managing Potential Drug Interactions of Nirmatrelvir/Ritonavir in COVID-19 Patients: A Perspective from an Israeli Cross-Sector Collaboration. Clin Pharmacol Ther. 2022;112(6):1156–1158.
   Google Scholar
• Coulson JM, Adams A, Gray LA, et al. COVID-19 “Rebound” associated with nirmatrelvir/ritonavir pre-hospital therapy. J Infect. 2022;85(4):436–480.
   Google Scholar
• Ganatra S, Dani SS, Ahmad J, et al. Oral Nirmatrelvir and Ritonavir in Non-hospitalized Vaccinated Patients with Covid-19. Clin Infect Dis. 2023;76(4):563–572.
   Google Scholar
• Malden DE, Hong V, Lewin BJ, et al. Hospitalization and Emergency Department Encounters for COVID-19 After Paxlovid Treatment - California, December 2021-May 2022. MMWR Morb Mortal Wkly Rep. 2022;71(25):830–833.
   PubMedGoogle Scholar
• Iketani S, Mohri H, Culbertson B, et al. Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir. Nature. 2023;613(7944):558–564.
   PubMed Web of Science ®Google Scholar
• Chavda VP, Vuppu S, Mishra T, et al. Recent review of COVID-19 management: diagnosis, treatment and vaccination. Pharmacol Rep. 2022;74(6):1120–1148.
   PubMedGoogle Scholar
• McCarthy MW. Optimizing the use of Paxlovid in clinical practice. Drugs Today (Barc). 2022;58(11):539–546.
   PubMed Web of Science ®Google Scholar
• Fischer W, Eron JJ, Holman W, et al. Molnupiravir, an Oral Antiviral Treatment for COVID-19. medRxiv. 2021.
   Google Scholar
• Fischer WA, Eron JJ, Holman W, et al. A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus. Sci Transl Med. 2022;14(628):eabl7430.
   PubMed Web of Science ®Google Scholar
• Singh AK, Singh A, Singh R, et al. An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19. Diabetes Metab Syndr. 2022;16(2):102396.
   PubMed Web of Science ®Google Scholar
• Ho WS, Zhang R, Tan YL, et al. and the promise of small molecule therapeutics: are there lessons to be learnt? Pharmacol Res. 2022;179:106201.
   PubMedGoogle Scholar
• Hui DSC, Zumla A. Advances in the epidemiology, clinical features, diagnosis, clinical management and prevention of coronavirus disease 2019. Curr Opin Pulm Med. 2022;28(3):166–173.
   PubMedGoogle Scholar
• Hashemian SMR, Pourhanifeh MH, Hamblin MR, et al. RdRp inhibitors and COVID-19: is molnupiravir a good option? Biomed Pharmacother. 2022;146:112517.
   PubMed Web of Science ®Google Scholar
• Al-Taie A, Denkdemir FR, Sharief Z, et al. The Long View on COVID-19 Theranostics and Oral Antivirals: living with Endemic Disease and Lessons from Molnupiravir. OMICS. 2022;26(6):324–328.
   PubMedGoogle Scholar
• Kaduszkiewicz H, Kochen MM, Kluge S, et al. Clinical Practice Guideline: recommendations for the Outpatient Drug Treatment of Patients With COVID-19. Dtsch Arztebl Int. 2022;19(Forthcoming):342.
   Google Scholar
• Bartoletti M, Azap O, Barac A, et al. ESCMID COVID-19 living guidelines: drug treatment and clinical management. Clin Microbiol Infect. 2022;28(2):222–238.
   PubMed Web of Science ®Google Scholar
• Vangeel L, Chiu W, De Jonghe S, et al. Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern. Antiviral Res. 2022;198:105252.
   PubMed Web of Science ®Google Scholar
• Parums DV. Editorial: current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Patients. Med Sci Monit. 2022;28:e935952.
   PubMed Web of Science ®Google Scholar
• Imai M, Ito M, Kiso M, et al. Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB. N Engl J Med. 2023;388(1):89–91.
   PubMed Web of Science ®Google Scholar
• Pereta I, Morancho A, López N, et al. Hospital at home treatment with remdesivir for patients with COVID-19: real-life experience. Int J Infect Dis. 2023;127:124–128.
   PubMedGoogle Scholar
• Lucijanic M, Cikara T, Bistrovic P, et al. Remdesivir use in COVID-19 patients might predispose bacteremia, matched case-control analysis. J Infect. 2022;85(2):174–211.
   PubMedGoogle Scholar
• Xie Y, Yin W, Zhang Y, et al. Design and development of an oral remdesivir derivative VV116 against SARS-CoV-2. Cell Res. 2021;31(11):1212–1214.
   PubMedGoogle Scholar
• Zhang R, Zhang Y, Zheng W, et al. Oral remdesivir derivative VV116 is a potent inhibitor of respiratory syncytial virus with efficacy in mouse model. Signal Transduct Target Ther. 2022;7(1):123.
   PubMedGoogle Scholar
• Qian HJ, Wang Y, Zhang MQ, et al. Safety, tolerability, and pharmacokinetics of VV116, an oral nucleoside analog against SARS-CoV-2, in Chinese healthy subjects. Acta Pharmacol Sin. 2022;43(12):3130–3138.
   PubMedGoogle Scholar
• Shen Y, Ai J, Lin N, et al. An open, prospective cohort study of VV116 in Chinese participants infected with SARS-CoV-2 omicron variants. Emerg Microbes Infect. 2022;11(1):1518–1523.
   PubMed Web of Science ®Google Scholar
• Cao Z, Gao W, Bao H, et al. VV116 versus Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19. N Engl J Med. 2023;388(5):406–417.
   PubMed Web of Science ®Google Scholar
• An K, Guo P, Qiu S, et al. Optimal duration of dual antiplatelet therapy followed by monotherapy in diabetic patients after percutaneous coronary intervention with drug‑eluting stent implantation: a Bayesian network meta-analysis. Pol Arch Intern Med. 2021;131(9):781–789.
   PubMedGoogle Scholar
• Cao Z, Gao W, Bao H, et al. VV116 versus Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19. N Engl J Med. 2023;388(5):406–417 .
   Google Scholar
• Cox RM, Wolf JD, Lieber CM, et al. Oral prodrug of remdesivir parent GS-441524 is efficacious against SARS-CoV-2 in ferrets. Nat Commun. 2021;12(1):6415.
   PubMedGoogle Scholar
• Planas D, Bruel T, Staropoli I, et al. Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies. bioRxiv. 2022;14(1):824.
   Google Scholar
• Qu P, Evans JP, Faraone J, et al. Distinct Neutralizing Antibody Escape of SARS-CoV-2 Omicron Subvariants BQ.1, BQ.1.1, BA.4.6, BF.7 and BA.2.75.2. bioRxiv. 2022;2022.
   Google Scholar
• Qu P, Evans JP, Faraone JN, et al. Enhanced neutralization resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2. Cell Host Microbe. 2023;31(1):9–17.e3.
   PubMedGoogle Scholar
• Fogh K, Larsen TG, Hansen CB, et al. Self-reported long COVID and its association with the presence of SARS-CoV-2 antibodies in a Danish cohort up to 12 months after infection. Microbiol Spectr. 2022;10(6):e0253722.
   PubMedGoogle Scholar
• Guntur VP, Nemkov T, de Boer E, et al. Signatures of mitochondrial dysfunction and impaired fatty acid metabolism in plasma of patients with post-acute sequelae of COVID-19 (PASC). Metabolites. 2022;12:11.
   Google Scholar
• Jimeno-Almazán A, Pallarés JG, Á B-R, et al. Post-COVID-19 syndrome and the potential benefits of exercise. Int J Environ Res Public Health. 2021;18:10.
   Google Scholar
• Ashour NA, Abo Elmaaty A, Sarhan AA, et al. A systematic review of the global intervention for sars-cov-2 combating: from drugs repurposing to molnupiravir approval. Drug Des Devel Ther. 2022;16:685–715.
   PubMed Web of Science ®Google Scholar
• Al-Karmalawy AA, Soltane R, Abo Elmaaty A, et al. Coronavirus disease (COVID-19) control between drug repurposing and vaccination: a comprehensive overview. Vaccines (Basel). 2021;9:11.
   Google Scholar